British Journal of Pharmacology, EarlyView.Abstract The past decade has seen a huge increase in clinical research with psychedelic drugs and 3,4‐methylenedioxymethamphetamine (MDMA), which have revealed great potential for treating mental health conditions. Given this progress in research, as well as the current unmet clinical need of millions of patients, in 2023, the Australian Therapeutic ...
David J Nutt +3 more
wiley +1 more source
Free energy calculations of the functional selectivity of 5-HT2B G protein-coupled receptor.
PLoS ONE, 2020 G Protein-Coupled Receptors (GPCRs) mediate intracellular signaling in response to extracellular ligand binding and are the target of one-third of approved drugs.
Brandon L Peters +2 more
doaj +1 more source
Molecular docking and binding interaction between psychedelic drugs and human serum albumin
BioTechnologia, 2020 Drug-plasma protein interaction is a critical concern in monitoring drug circulation and drug-drug interactions. The present study aimed to investigate the interaction of psychedelic drugs such as lysergic acid diethylamide (LSD), dimethyltryptamine (DMT)
Hossein Khastar +4 more
doaj +1 more source
Lower-dose psycholytic therapy – A neglected approach
Frontiers in Psychiatry, 2022 Lysergic acid diethylamide (LSD) and similar psychoactive drugs have been used in psychotherapy since 1949, when the first clinical study with lower-dose LSD showed therapeutically relevant effects.
Torsten Passie +6 more
doaj +1 more source
Psilocybin as a novel treatment for chronic pain
British Journal of Pharmacology, EarlyView.Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain.
Tate Askey +3 more
wiley +1 more source
Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials
Frontiers in Psychiatry, 2020 Lysergic acid diethylamide (LSD) was studied from the 1950s to the 1970s to evaluate behavioral and personality changes, as well as remission of psychiatric symptoms in various disorders.
Juan José Fuentes +10 more
doaj +1 more source
LSD: An Analysis of the Literature Concerning its Use in the Therapy of Alcoholism [PDF]
, 1967 It will be the concern of this paper to explore the use of the chemical d-lysergic acid diethylamide-25 in therapeutic regimes for ...
Lyddon, Patti
core +1 more source
Novel Psychoactive Substances 14Recent Progress on Neuropharmacological Mechanisms of Action for Selected Drugs [PDF]
, 2017 A feature of human culture is that we can learn to consume chemical compounds, derived from natural plants or synthetic fabrication, for their psychoactive effects.
Boris B. , Quednow +8 more
core +1 more source
Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT2A receptor agonists
British Journal of Pharmacology, EarlyView.Psychedelic drugs such as LSD and psilocin were once relegated to the fringes of medical research because of their association with counterculture movements and a perceived concern about harm through recreational use, and their consequent legal prohibition in the early 1970s.
Trevor Sharp, Aurelija Ippolito
wiley +1 more source
Pengaruh Lysergic Acid Diethylamide Yang Terdapat Pada Lem Eha-bond Terhadap Kualitas Spermatozoa Wistar Jantan (Rattus Norvegicus) [PDF]
, 2015 : Lysergic Acid Diethylamide (LSD) is a psychotropic drug that can be found in glue. This substance acts as serotonine and dopamine agonists and results in hallucinogenic effect.
Budiono, A. (Alfred) +2 more
core